Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trofinetide for Rett Syndrome (LAVENDER)
NCT04181723Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trofinetide in Rett syndrome (RTT), sponsored by Acadia Pharmaceuticals. Started Nov 2019; status: completed.
02
Drugs
trofinetide
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT04181723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181723.